Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

American Shared Hospital Services Closes Sale of Its Gamma Knife Business in Turkey

AMS

AMERICAN SHARED HOSPITAL SERVICES (NYSE MKT:AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that it has closed the sale of its Gamma Knife and Image Guided Radiation Therapy (IGRT) services business in Turkey to Euromedic Cancer Treatment Centers BV (Euromedic). Payment to AMS consisted of cash, which will be used primarily to pay down debt associated with the Turkey operations, and an earn-out based on future revenue from the two Gamma Knife units and one IGRT unit AMS operated in Istanbul and Adana, Turkey.

“We anticipate that the earn-out portion of the transaction may generate considerable returns for AMS over the next few years,” said AMS Chairman and Chief Executive Officer Ernest A. Bates, M.D.

About AMS

American Shared Hospital Services provides turnkey technology solutions for advanced radiosurgical and radiation therapy services. AMS is the world leader in providing Gamma Knife radiosurgery equipment, a non-invasive treatment for malignant and benign brain tumors, vascular malformations and trigeminal neuralgia (facial pain). The Company also offers the latest IGRT and IMRT systems, as well as its proprietary Operating Room for the 21st CenturySM concept. AMS owns a common stock investment in Mevion Medical Systems, Inc., developer of the compact MEVION S250 Proton Therapy System.

About Euromedic

Euromedic is one of the largest healthcare investors and operators through Private Public Partnerships (PPP) in Europe. The company performs best-in-class radiological diagnostic, clinical laboratory and cancer care services in 145 wholly-owned medical centers. The company is continually growing and driving treatment delivery to areas where none yet exists.

Euromedic International is a Dutch holding company that employs more than 3,000 medical professionals. The company operates diagnostic, clinical laboratory and cancer care (radiotherapy) centers in Poland, Hungary, Romania, Bosnia and Herzegovina, Croatia, Greece, Italy, Turkey, the Czech Republic, Ireland, Switzerland, Lithuania, Bulgaria and Portugal. Euromedic activities are divided into three divisions - Euromedic Diagnostics, which operates diagnostic centers, Euromedic Cancer Care Centres, which provide state-of-the-art comprehensive cancer treatment services, and Euromedic Labs, which provide high-quality laboratory investigations. Euromedic is audited by E&Y and its centers operate strictly according to the globally accepted standard – ISO 9001. Visit www.euromedic.com for more information.

The Company’s shareholders

Euromedic’s success is due to its commitment to using the best technology available, employing the best local experts in their field, and ultimately doing the best for the patient. However, it is also due to exemplary corporate governance. The shareholders of Euromedic are among the largest private equity groups in the world and, together with Euromedic management, drive the success and growth of the company.

Ares Life Sciences (Ares) is a Jersey-based investment partnership established in 2008 with the backing of the Bertarelli family. Ares focuses its investment activities exclusively on revenue-generating life sciences companies, primarily in Europe, with the presence or capacity to expand internationally. In the life sciences sector, Ares' main interest is in biotechnology, pharmaceuticals, medical technology and healthcare services. Ares is advised by a team of experienced life science and investment executives. Visit www.areslifesciences.com for more information.

Montagu Private Equity is one of Europe’s leading private equity firms. Founded in 1968, Montagu can look back on more than 40 years’ experience, investing in more than 400 transactions. Montagu has a strong track record of supporting portfolio companies, dedicating significant resource to management teams, as well as providing additional capital expenditure to fund further growth. Montagu also has considerable expertise in helping businesses to accelerate their growth in their home markets, as well as to internationalise and expand their customer base. This approach has led to real growth across Montagu’s portfolio. The firm has assets under management of €3.3 billion. Montagu invests in businesses that operate in stable markets across Europe with transaction values ranging from approximately €100 million to €1 billion. Visit www.montagu.com for more information.

Safe Harbor Statement

This press release may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American Shared Hospital Services, which involve risks and uncertainties including, but not limited to, the risks of the Gamma Knife and radiation therapy businesses, the risks of developing The Operating Room for the 21st Century program, and the risks of investing in a development-stage company, Mevion Medical Systems, Inc. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2013, the Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 and the definitive Proxy Statement for the Annual Meeting of Shareholders to be held on June 10, 2014.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today